5 unknown. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 5 |
| Phase 2 | 2 | Unknown 2 |
Follow dalpiciclib: new trials by email Literature Review of dalpiciclib trials Research Report on dalpiciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg - Esophageal Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 6 | 2023-12-29 | 2024-03-06 |
| Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg - Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 6 | 2023-10-31 | 2024-07-23 |
| Study of SHR6390 in Renal Insufficiency and Healthy Subjects SHR6390 - Breast Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 30 | 2022-12-18 | 2023-03-10 |
| Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer Dalpiciclib, Fulvestrant, Pertuzumab - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 72 | 2022-09-01 | 2024-02-26 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 59 | 2019-05-12 | 2023-03-07 |
Breast Neoplasms (3) · Esophageal Squamous Cell Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Fudan University (2) · West China Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (1)
China (5)